Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2023
(5 months ago) | |
US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2024
(6 days from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11504365 | AVEO PHARMS | Use of tivozanib to treat subjects with refractory cancer |
Nov, 2039
(15 years from now) |
Fotivda is owned by Aveo Pharms.
Fotivda contains Tivozanib Hydrochloride.
Fotivda has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Fotivda are:
Fotivda was authorised for market use on 10 March, 2021.
Fotivda is available in capsule;oral dosage forms.
Fotivda can be used as treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally for 21 days followed by no drug for 7 days, a method of treating adults with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies by inhibiting the angiogenesis of blood vessels with a vascular endothelial growth factor inhibitor.
Drug patent challenges can be filed against Fotivda from 10 March, 2025.
The generics of Fotivda are possible to be released after 05 November, 2039.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
Dosage: CAPSULE;ORAL